SOUTH SAN FRANCISCO, Calif. & MÖLNDAL, Sweden--(BUSINESS WIRE)-- Cellectricon AB and Fluxion Biosciences today announced that they have settled the patent infringement litigation that Cellectricon commenced against Fluxion in 2009.
Cellectricon and Fluxion have agreed to file a stipulation of dismissal with the United States District Court for the Northern District of California for all claims brought by Cellectricon against Fluxion for alleged infringement of Cellectricon’s U.S. Patent Nos. 7,390,650, 7,470,518, and 7,563,614. Under the terms of the settlement, Fluxion and Cellectricon will cross-license patents related to microfluidic cellular analysis.
"We are very pleased to have achieved a successful conclusion to the litigation," said David A. Burns, Chief Executive Officer of Cellectricon. "Resolution of this lawsuit allows us to focus on providing innovative and enabling products and discovery services for drug discovery and life science research globally."
"Fluxion couldn't be more pleased with the settlement and the outcome of the litigation. We believe it is a win-win for both companies, and will benefit our customers as we can now focus all of our attention on developing and providing solutions that continue to deliver maximum benefit to them," said Jeff Jensen, CEO of Fluxion Biosciences.
Cellectricon is a leading provider of advanced cell-based screening technologies and services to accelerate drug discovery and cell-based assay research. Our proprietary technologies include leading systems for high resolution ion-channel screening and cell engineering. Developed in close collaboration with leaders in the pharmaceutical industry and esteemed research labs, the Cellaxess® Technology enables scalable field stimulation, compound delivery and transfection for genomic screening of primary cells, neurones and stem cells. The Dynaflow® Technology advances ion channel research and discovery applications.
About Fluxion Biosciences
Fluxion Biosciences develops cellular analysis tools for use in critical applications in life sciences research and drug discovery. Fluxion's technology facilitates the characterization of molecular and cellular mechanisms in physiologically relevant microenvironments. Fluxion helps to bridge the translational biology gap by bringing research data closer to patients and clinical trials. Our innovative BioFlux, IonFlux, and IsoFlux systems for live cell analysis are enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests. For more information about Fluxion Biosciences, visit www.fluxionbio.com.
Tom Driscoll, 650-241-4777
VP Marketing & Business Development
Source: Fluxion Biosciences